BioDlink Biopharm Co Ltd, a China-based Contract Development and Manufacturing Organisation (CDMO), announced on Friday that it has been recognised as 'Emerging CDMO of the Year' at the Asia-Pacific Biopharma Excellence Awards, organised by IMAPAC.

This recognition underscores BioDlink's growing role as a trusted development and manufacturing partner for global biopharmaceutical innovators, the company said. BioDlink provides integrated solutions for complex biologics and antibody-drug conjugates (ADCs), supporting programs from early research and technology evaluation through process development, analytical development and manufacturing.

The Asia-Pacific Biopharma Excellence Awards aim to celebrate excellence and innovation across the biopharmaceutical industry in the Asia-Pacific region. The awards recognise organisations that demonstrate outstanding technological capabilities, operational excellence, and leadership in advancing biopharma development and manufacturing.